A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and ...

Short interest in Lantheus Holdings Inc (NASDAQ:LNTH) decreased during the last reporting period, falling from 6.46M to 6.42M. This put 12.34% of the company's publicly available shares short.

Shares of Lantheus stock opened at $93.41 on Wednesday. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The company’s 50-day moving average price is $93.32 and ...

And in light of that, the trends we're seeing at Lantheus Holdings' (NASDAQ:LNTH) look very promising so lets take a look. The end of cancer? These 15 emerging AI stocks are developing tech that ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...